Today: 7 February 2026
Subscribe

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
India may let Chinese firms bid again for $750 billion in contracts — BHEL hits limit downNEW DELHI,

India may let Chinese firms bid again for $750 billion in contracts — BHEL hits limit downNEW DELHI,

BHEL shares hit the 10% lower circuit on Thursday after reports India may ease restrictions on Chinese firms bidding for government contracts. Siemens shares fell over 3%. The finance ministry is considering scrapping rules imposed after the 2020 border clash, sources said. India’s Nifty 50 dropped 1% and the Sensex lost 0.9% as markets reacted to the policy debate and U.S. tariff threats.
8 January 2026
Lockheed Martin stock jumps premarket after Trump’s $1.5 trillion defense-budget call

Lockheed Martin stock jumps premarket after Trump’s $1.5 trillion defense-budget call

Lockheed Martin shares surged 7.6% to $534.78 in premarket trading Thursday after Trump proposed a $1.5 trillion military budget for 2027 and signed an order restricting defense contractor buybacks and dividends. The stock had closed Wednesday down 4.8%. Lockheed reported delivering 191 F-35 jets in 2025, up from 110 in 2024. Investors await Lockheed’s earnings on Jan. 29.
8 January 2026
··
Intel stock hits a 52-week high on 18A Panther Lake debut as Jan. 22 earnings loom

Intel stock hits a 52-week high on 18A Panther Lake debut as Jan. 22 earnings loom

Intel shares surged 6.5% to $42.63 Wednesday, hitting a 52-week high after heavy trading on news of its first 18A-based laptop platform. Volume reached 166 million shares, 2.5 times Tuesday’s level. Intel unveiled its Core Ultra Series 3 “Panther Lake” processors at CES, with global availability set for Jan. 27. Melius upgraded the stock to “buy” and set a $50 target.
8 January 2026
··
Applied Digital stock: APLD jumps after-hours on revenue beat, $5B AI lease and fresh funding

Applied Digital stock: APLD jumps after-hours on revenue beat, $5B AI lease and fresh funding

Applied Digital shares jumped about 7% after hours as Q2 revenue reached $126.6 million, beating analyst estimates. The company booked $85 million from its high-performance computing unit, mostly from customer fit-out work and early lease revenue. Applied Digital ended the quarter with $2.3 billion in cash and $2.6 billion in debt. Investors are watching the pace at which long-term leases convert to recurring rent.
8 January 2026
··
Blackstone stock steadies in premarket after Trump threatens Wall Street home-buying ban

Blackstone stock steadies in premarket after Trump threatens Wall Street home-buying ban

Blackstone shares were unchanged at $153.59 in premarket trading Thursday after a 5.6% drop Wednesday, triggered by Donald Trump’s pledge to ban institutional investors from buying single-family homes. The stock had fallen as low as $147.52 during the previous session. Investors await U.S. jobs data Friday and Blackstone’s quarterly results on Jan. 29.
8 January 2026
···
British American Tobacco stock edges up after fresh buyback update as Feb results loom

British American Tobacco stock edges up after fresh buyback update as Feb results loom

British American Tobacco shares rose 0.3% to 3,979 pence by 0933 GMT after disclosing it bought 158,668 shares on Jan. 7 at an average price of 3,981.70 pence. The move trimmed a two-day slide, though the stock remains below 4,000 pence. In the U.S., its ADR fell 1.4% premarket. BAT’s buyback comes as management signals caution for 2026 revenue amid U.S. vape competition and regulation.
8 January 2026
····
UK Retail Shakeout Starts Fast: 2,550 Jobs at Risk as Supermarkets Battle for Share

UK Retail Shakeout Starts Fast: 2,550 Jobs at Risk as Supermarkets Battle for Share

Claire’s and The Original Factory Shop have entered administration, putting about 2,550 jobs at risk across nearly 300 UK stores. Tesco raised its profit outlook after a 3.2% rise in UK sales over Christmas, while Sainsbury’s and Marks & Spencer reported stronger food sales but weaker non-food results. Asda’s sales fell 4.2% and its market share slipped to 11.4%.
8 January 2026
··
Standard Chartered stock edges up after buyback update; STAN.L investors eye Feb results

Standard Chartered stock edges up after buyback update; STAN.L investors eye Feb results

Standard Chartered shares rose 0.8% to 1,805 pence in early London trade after the bank bought back 537,006 shares, bringing total buyback spending to $1.11 billion. The buyback program, launched in August, is now about 86% complete and runs through Jan. 31. Full-year results are due Feb. 24. The bank also announced terms for three new bond issues under its $77.5 billion debt program.
8 January 2026
··
Jefferies lifts Barclays, Lloyds and NatWest price targets as UK bank rally rolls into 2026

Jefferies lifts Barclays, Lloyds and NatWest price targets as UK bank rally rolls into 2026

Jefferies raised price targets on Barclays to 560p, Lloyds to 119p, and NatWest to 720p, citing room for UK bank shares to rise. UK banks now account for 17% of the FTSE 100 but still trade at a 25% discount to the wider market. Barclays kept Lloyds rated “overweight” and cut NatWest to “equal weight,” citing stronger capital returns at Lloyds. Shares were mixed in early London trading.
8 January 2026
····
1 … 509 510 511 512 513 … 1,634

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop